3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Breast
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Breast Neoplasms
1
Interventions
Trastuzumab
87
Cyclophosphamide
67
Capecitabine
67
Paclitaxel
64
Docetaxel
58
Fulvestrant
52
Letrozole
50
Carboplatin
42
pembrolizumab
41
Lapatinib
38
Doxorubicin
36
Anastrozole
32
Vinorelbine
31
Bevacizumab
31
exemestane
28
Tamoxifen
25
Gemcitabine
25
Albumin-Bound Paclitaxel
25
Radiotherapy
21
Taxes
19
atezolizumab
18
pertuzumab
17
Everolimus
17
130-nm albumin-bound paclitaxel
17
Epirubicin
16
palbociclib
15
Magnetic Resonance Spectroscopy
15
eribulin
14
Ado-Trastuzumab Emtansine
14
Goserelin
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
AZD 8931
×
Breast
×
Clear all
NCT01151215
2014-07-25
MINT
AstraZeneca
Phase 2
Terminated
482 enrolled
10 charts